Вже доступно! Дослідження Telegram за 2025 — головні інсайти року 
LIFE AI Announcement
Відкрити в Telegram
The Intelligence Layer of Human Health - Avalanche’s flagship L1 for Healthcare AI. Twitter: https://twitter.com/LifeNetwork_AI Group: @lifenetwork_group
Показати більшеКраїна не вказанаМедицина378
📈 Аналітичний огляд Telegram-каналу LIFE AI Announcement
Канал LIFE AI Announcement (@lifenetwork_ann) у мовному сегменті Англійська є активним учасником. На даний момент спільнота об'єднує 44 922 підписників, посідаючи 378 місце в категорії Медицина.
📊 Показники аудиторії та динаміка
З моменту свого створення невідомо, проект продемонстрував стрімке зростання, зібравши аудиторію у 44 922 підписників.
За останніми даними від 23 червня, 2026, канал демонструє стабільну активність. Хоча за останні 30 днів спостерігається зміна кількості учасників на -966, а за останні 24 години на -35, загальне охоплення залишається високим.
- Статус верифікації: Верифікований (Офіційно підтверджено Telegram)
- Рівень залученості (ER): Середній показник залученості аудиторії становить 2.12%. Протягом перших 24 годин після публікації контент зазвичай збирає 0.66% реакцій від загальної кількості підписників.
- Охоплення публікацій: В середньому кожен допис отримує 954 переглядів. Протягом першої доби публікація в середньому набирає 297 переглядів.
- Реакції та взаємодія: Аудиторія активно підтримує контент: середня кількість реакцій на один пост – 27.
- Тематичні інтереси: Контент зосереджений навколо ключових тем, таких як healthcare, testnet, infrastructure, layer, nvidia.
📝 Опис та контентна політика
Автор описує ресурс як майданчик для висловлення суб'єктивної думки:
“The Intelligence Layer of Human Health - Avalanche’s flagship L1 for Healthcare AI.
Twitter: https://twitter.com/LifeNetwork_AI
Group: @lifenetwork_group”
Завдяки високій частоті оновлень (останні дані отримано 24 червня, 2026), канал підтримує актуальність та високий рівень охоплення публікацій. Аналітика показує, що аудиторія активно взаємодіє з контентом, що робить його важливою точкою впливу в категорії Медицина.
44 922
Підписники
-3524 години
-2357 днів
-96630 день
Триває завантаження даних...
Схожі канали
Немає даних
Виникли проблеми? Будь ласка, оновіть сторінку або зверніться до нашого support-менеджера.
Хмара тегів
Вхідні та вихідні згадування
---
---
---
---
---
---
Залучення підписників
червень '26
червень '260
в 0 каналах
травень '26
+3
в 0 каналах
Get PRO
квітень '260
в 0 каналах
Get PRO
березень '26
+46
в 0 каналах
Get PRO
лютий '26
+191
в 0 каналах
Get PRO
січень '26
+640
в 0 каналах
Get PRO
грудень '25
+10 226
в 0 каналах
Get PRO
листопад '25
+2 969
в 2 каналах
Get PRO
жовтень '25
+34 208
в 1 каналах
Get PRO
вересень '25
+1
в 0 каналах
Get PRO
серпень '25
+2
в 0 каналах
Get PRO
липень '250
в 0 каналах
Get PRO
червень '250
в 0 каналах
Get PRO
травень '250
в 0 каналах
Get PRO
квітень '25
+38
в 0 каналах
Get PRO
березень '25
+14
в 0 каналах
Get PRO
лютий '250
в 1 каналах
Get PRO
січень '250
в 0 каналах
Get PRO
грудень '24
+7
в 0 каналах
Get PRO
листопад '240
в 0 каналах
Get PRO
жовтень '24
+10 036
в 2 каналах
Get PRO
вересень '24
+20 763
в 4 каналах
| Дата | Залучення підписників | Згадування | Канали | |
| 24 червня | 0 | |||
| 23 червня | 0 | |||
| 22 червня | 0 | |||
| 21 червня | 0 | |||
| 20 червня | 0 | |||
| 19 червня | 0 | |||
| 18 червня | 0 | |||
| 17 червня | 0 | |||
| 16 червня | 0 | |||
| 15 червня | 0 | |||
| 14 червня | 0 | |||
| 13 червня | 0 | |||
| 12 червня | 0 | |||
| 11 червня | 0 | |||
| 10 червня | 0 | |||
| 09 червня | 0 | |||
| 08 червня | 0 | |||
| 07 червня | 0 | |||
| 06 червня | 0 | |||
| 05 червня | 0 | |||
| 04 червня | 0 | |||
| 03 червня | 0 | |||
| 02 червня | 0 | |||
| 01 червня | 0 |
Дописи каналу
Every clinical trial is a controlled experiment.
That is its strength. It is also its limit.
Trials recruit narrow populations: younger, healthier patients with fewer comorbidities and fewer medications than the people who will eventually use the drug.
This is not a flaw in design. It is a structural consequence of how controlled evidence works.
A drug that performs well in that population gets approved.
The patient who receives it in clinical practice is often someone the trial never tested.
This gap has a name: real world evidence.
Most of the industry measures it only after approval, too late to inform the decisions that mattered most.
Validating therapies in populations that more closely reflect real patients before approval can change what gets approved and who actually benefits from it.
| 2 |  A drug spends years in trials, then decades in the real world.
The real world generates far more evidence about how it actually performs than any trial.
That evidence rarely goes anywhere.
Which patients respond. What side effects emerge. How it behaves across populations the trial never tested.
The most valuable evidence in the entire lifecycle — and it almost never flows back into what gets discovered or trialed next.
Every new program starts from the same incomplete picture as the last.
AI can generate more candidates than ever. But a pipeline that can’t learn from its own history won’t produce a different outcome.
The missing infrastructure isn’t discovery. It’s the loop back. | 626 |
| 3 |  In the last 30 years, computing power has increased by a factor of a trillion.
Yet developing a new therapy remains one of the slowest, most expensive, and most failure-prone processes in modern science.
This is the paradox worth understanding.
AI has accelerated target identification. Gene sequencing has collapsed from years to days. Computational modeling can simulate molecular interactions at a scale that was unimaginable a decade ago.
Yet the pipeline moves at the same pace.
The reason is that technology has made individual stages of the process faster. What it has not changed is the structure of the process itself.
Drug development is still sequential. Each stage waits for the one before it. Each program still assembles its own evidence infrastructure from scratch. The handoff between controlled validation and real-world performance still happens after approval.
Better tools applied to a fragmented, sequential process produce better science at the same speed.
What compresses the timeline is not faster tools inside the existing structure. It is a different structure entirely. | 687 |
| 4 |  AI can now generate drug candidates at a scale the industry has never seen.
But the number of drugs reaching patients has not changed.
The pipeline is fuller than ever. The outcome is the same.
Validation still takes years.
Trials still require building evidence from scratch.
And the real-world signal that determines whether a drug actually works for real patients still arrives too late to change anything.
More discovery without better infrastructure doesn’t accelerate medicine.
It creates a longer queue. | 797 |
| 5 |  Clinical trials are the most expensive phase of drug development. They are also the phase most likely to fail.
Phase I: testing safety in a small group.
Phase II: testing efficacy in a larger group.
Phase III: confirming results across a broad population.
Each phase takes years. Each phase requires recruiting participants who fit narrow eligibility criteria. And each phase validates a drug against a controlled population that rarely reflects the biological diversity of the patients it will eventually serve.
This is the fundamental problem with how clinical trials are designed.
The evidence is generated in a controlled environment. The drug is deployed in the real world. The gap between those two contexts is where most post-market failures begin.
Real-world validation — continuous, population-diverse, outside the trial — is not a supplement to clinical trials. It is what makes the evidence from clinical trials actually predictive. | 1 059 |
| 6 |  Bringing a single drug to market takes 12 to 15 years and costs up to $2.6 billion. Despite that investment, 90% of drug candidates that enter clinical trials never reach approval.
The reason is not that the science is wrong. It is that the process was never designed to learn continuously.
The drug development lifecycle has 7 stages:
1. Target Discovery
2. Drug Discovery
3. Lead Optimization & Candidate Selection
4. Preclinical Research
5. Clinical Trials
6. Regulatory Review
7. Post-Market Monitoring & Patient Access
Every stage runs sequentially.
Every handoff introduces delay.
Every program builds its own evidence infrastructure from scratch.
And the real-world signal generated in stage 7 - how a drug actually performs in real patients never flows back to inform the decisions made in stages 1 through 3.
That missing feedback loop is where most of the time, cost, and failure lives. | 1 049 |
| 7 |  If the problem is coordination across an entire healthcare value chain, the infrastructure has to be built for that from the ground up.
That is what Life AI is. The shared infrastructure and coordination layer that connects pharma, hospitals, doctors, labs, regulators, auditors, and patients, with their interests aligned around each application's success.
At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao took the stage to present exactly how Life AI is building that infrastructure and why it matters for the future of healthcare. | 1 115 |
| 8 |  Building a better AI model will not fix healthcare.
The real challenge is coordinating an entire value chain: pharma, hospitals, doctors, labs, regulators, auditors, and patients. Each with its own incentives, priorities, compliance obligations, and trust requirements.
No single model can coordinate all of that. No single organization can either.
Better healthcare comes from better infrastructure for the value chain.
That is the problem Life AI was built to solve. | 1 066 |
| 9 |  Healthcare has AI in every vertical.
AI doctors. AI diagnostics. AI copilots. AI imaging. AI drug discovery. AI trial matching. AI revenue cycle.
Yet healthcare still looks mostly the same.
Cancer is not yet cured. Drug prices are not yet lowered. Care is not yet personalized.
AI is transforming every industry. Why not yet healthcare?
That is the question Dr. Tuan Cao, Co-Founder & CEO of Life AI, posed at NVIDIA GTC Taiwan 2026 and the problem Life AI is building to solve. | 1 047 |
| 10 |  +4𝗡𝗩𝗜𝗗𝗜𝗔 𝗚𝗧𝗖 𝗧𝗮𝗶𝘄𝗮𝗻 𝟮𝟬𝟮𝟲 - 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 #𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻
At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao presented “LifeAI Biohub: A Purpose-built AI platform for Drug Development”
One signal emerged throughout the session:
As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders.
𝗧𝗵𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻
Pharma → Hospitals → Doctors → Labs → Regulators → Auditors → Patients
Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization.
𝗟𝗶𝗳𝗲𝗔𝗜 𝗕𝗶𝗼𝗛𝘂𝗯
Shared Infrastructure → Coordination Layer → Connected Network → Application Success
This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry.
The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale.
It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI. | 1 155 |
| 11 |  +3Life AI at GStar Summit 2026
Life AI participated in GStar Summit 2026: AI + Humanity, where our Co-Founder & CEO, Dr. Tuan Cao, joined the AI for Healthcare & Life Sciences session.
The discussion explored the opportunities and responsibilities of applying AI in healthcare and life sciences, especially as the industry moves toward more personalized, preventive, and data-driven models of care.
For Life AI, this conversation aligns closely with our mission to build AI-native healthcare infrastructure that supports better coordination, deeper health intelligence, and improved real-world outcomes.
We were glad to be part of a forum bringing together leaders, researchers, and innovators shaping the future of responsible AI. | 1 171 |
| 12 |  AI learns. Humans decide.
We didn’t build Life AI to replace clinicians.
We built it to change what is possible for human health — infrastructure that coordinates across biology, institutions, and real human life.
The AI is the coordination layer. The human is the reason it exists. | 1 187 |
| 13 |  AI in prior authorization is not a productivity issue.
It is an access-to-care issue.
When automation is used to review, delay, or deny care, the stakes are different from ordinary back-office AI.
The system is no longer just processing paperwork.
It is influencing whether patients receive treatment, how long they wait, and how much administrative burden is pushed onto clinicians and families.
This is where healthcare AI needs a higher governance standard.
Speed is not enough.
AI used in prior authorization must be transparent, appealable, auditable, and clinically accountable.
Health systems and regulators should ask:
Who reviews adverse decisions?
Can patients and clinicians understand why care was delayed?
Are denial patterns monitored?
Is there human oversight when medical necessity is involved?
Can the system prove it improves efficiency without restricting appropriate care?
AI that sits between a patient and treatment cannot be governed like ordinary automation.
It must be governed as part of the care access infrastructure. | 1 269 |
| 14 |  Preventive care does not fail because people dislike prevention.
It fails because healthcare systems are built around episodes.
A visit.
A claim.
A lab result.
A discharge.
A diagnosis.
But health risk builds continuously.
Sleep changes.
Biomarkers drift.
Behavior shifts.
Medication adherence changes.
Inflammation rises.
Symptoms appear before diagnosis.
Preventive healthcare needs infrastructure that can detect trajectory changes before they become clinical events.
That requires longitudinal data, feedback loops, and earlier intervention pathways. | 1 147 |
| 15 |  Healthcare AI adoption is moving faster than healthcare AI governance.
That gap is not theoretical.
If a hospital deploys generative AI inside the EHR, it also needs capacity to monitor:
☑️ accuracy
☑️ bias
☑️ clinical safety
☑️ workflow impact
☑️ model drift
☑️ failure modes
☑️ patient trust
Healthcare AI cannot be treated like ordinary SaaS.
Deployment is not the finish line.
In healthcare, deployment is when the monitoring obligation begins. | 1 200 |
| 16 |  Healthcare was built around sickcare.
Life AI BioHub is built around lifecare.
Real-world learning. Early intervention. Integrated biology.
A coordination layer for human health. | 1 050 |
| 17 |  Clinician burnout is not only a workload problem.
It is often a coordination problem.
Too many clicks.
Too many handoffs.
Too many disconnected systems.
Too much information without prioritization.
Too much documentation that does not help the next decision.
AI in healthcare should not simply add another screen, alert, or assistant.
The real test is whether it reduces cognitive load inside the workflow.
If AI gives clinicians more things to check, it has failed operationally.
If it helps the system surface the right context at the right moment, it starts to matter. | 1 100 |
| 18 |  1/ Healthcare AI is often evaluated at the wrong layer.
The question is usually:
Did the model produce the right output?
But in healthcare, a correct output is only useful if the system can act on it.
2/ A risk score that does not change workflow is just a report.
A summary that does not reach the right team is just text.
A clinical note that does not improve follow-up, coding, or care continuity is just documentation.
3/ The better evaluation question is:
What operational behavior changed because AI was introduced?
Did it reduce delay?
Did it improve escalation?
Did it close a handoff gap?
Did it make context available sooner?
Did it improve learning from outcomes?
4/ Healthcare AI should be judged less like a feature demo and more like infrastructure.
Not only by output accuracy.
But by whether it improves the path from signal to decision to intervention. | 1 101 |
| 19 |  Honored to announce that our Co-Founder & CEO, Dr. Tuan Cao, will be speaking at GStar Summit 2026: AI + Humanity, co-organized by New Turing Institute and Pacific Gateway Partners, with Google as a strategic partner.
Session: AI for Healthcare & Life Sciences
Behind every piece of biological data is a real human being. AI can unlock extraordinary potential in healthcare but only when human dignity comes before model prediction.
📅 May 29, 2026
📍 Sheraton Saigon Grand Opera Hotel, Ho Chi Minh City
🎟️ Register: https://ticketbox.vn/gstar-summit-ai-humanity-2026-25943
Join over 1,000 leaders, researchers, and innovators working toward a more responsible AI future in Southeast Asia. | 1 342 |
| 20 |  Your body speaks before disease does.
We build to hear the signals earlier before symptoms appear, before diagnosis begins, before health turns into illness.
Life AI BioHub - built for lifecare. | 1 221 |
